Slingshot members are tracking this corporate initiative:
Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc. Acquisition
Do you think this event is important to the companies below? How will it affect their stock price?
As previously announced on May 31, 2016, Jazz Pharmaceuticals and Celator entered into a definitive merger agreement under which Jazz Pharmaceuticals has commenced a tender offer for all of the outstanding shares of Celator at $30.25 per share in cash, representing total consideration of approximately $1.5 billion. The expiration of the HSR waiting period satisfies one of the conditions required to consummate the tender offer. The closing of the tender offer remains subject to other customary conditions, including the tender of a majority of the outstanding shares of Celator common stock.The tender offer and withdrawal rights will expire at one minute following 11:59 p.m., New York City Time, on July 11, 2016, unless the tender offer is extended or terminated earlier in accordance with the terms of the definitive merger agreement. The Offer to Purchase dated June 10, 2016, relating to the tender offer has been filed with the United States Securities and Exchange Commission ("SEC") and can be viewed online, along with any amendments thereto, at www.sec.gov.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Jun 24, 2016 Projected Implementation: Q2, 2016 Relevance Tracked Until: Q3, 2016
Don’t see a project related to the strategic initiative you care about?
Related Keywords Hsr Waiting Period, Acquisition, Antitrust, Expiration